Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
ConclusionsBV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo ‐SCT, even after prior exposure to BV.
Source: Cancer - Category: Cancer & Oncology Authors: Ali Bazarbachi,
Ariane Boumendil,
Herv é Finel,
Mohamad Mohty,
Luca Castagna,
Didier Blaise,
Karl S. Peggs,
Boris Afanasyev,
J.L. Diez‐Martin,
Paolo Corradini,
David Michonneau,
Stephen Robinson,
Gonzalo Gutiérrez García,
Francesca Bonif Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Hodgkin's Disease | Lymphoma | Stem Cell Therapy | Stem Cells | Transplants